Short-term studies have shown that ...

Short-term studies have shown that oral magnesium addition s improve endothelial function. It is les clear if this meaning improves outcomes in patients with coronary artery disease (CAD). Shechter and associates compared the tenor of oral magnesium with placebo upon CAD outcomes by measuring exercise tolerance, exercise-induced ischemia, and quality of life.

Using a randomized, prospective, multicenter, double-blind, placebo-controlled trial enrolling 187 participants older than 20 years with stable CAD, twice-daily oral magnesium supplementation was compared with placebo. Patients continued all other medications and routine diet habits during the six-month study

Baseline magnesium evens were similar between the sum of two units groups but increased significantly in the participants receiving magnesium supplementation. The treatment assemblage had a significant improvement in exercise duration compared with no change in the placebo form into groups There was a significant decrease in exercise-induced chest pain and ST-segment depression at peak exercise in the treatment arrange Most quality-of-life parameters also improved in the treatment cluster There were no significant differences noted in lipid horizontals in either group after six month There was no increase in adverse occurrences in the treatment group.

The authors determine that in a patient arrange already receiving near-optimal care for CAD, magnesium therapy improved cardiac exercise tolerance, exercise-induced chest pain, and quality of life. Potential mechanisms that may be responsible for this beneficial meaning include improved intracellular adenosine triphosphate production, enhanced check of intracellular calcium changes, reduc systemic and pulmonary vascular resistance, reduc arteriolar tone, and mild reduction of systolic posterity pressure. It also is possible that CAD may be associated with excessive magnesium los and relative magnesium deficiency. Magnesium should be used as adjuvant therapy in patients with CAD.

Richard Sadovsky, MD

Shechter M et al. drifts of oral magnesium therapy in succession exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol March 1 2003;91:517-21

COPYRIGHT 2003 American Academy of Family Physicians

COPYRIGHT 2003 Gale Group